Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

Abstract

Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate‐specific antigen response. Follow‐up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. Conclusion This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer.

Keywords

• abiraterone acetate
• bone metastases
• castration resistant prostate cancer
• statin